These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37131012)

  • 21. Evaluation of quantitative signal detection in EudraVigilance for orphan drugs: possible risk of false negatives.
    Sardella M; Lungu C
    Ther Adv Drug Saf; 2019; 10():2042098619882819. PubMed ID: 31673326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A description of medicines-related safety issues evaluated through a referral procedure at the EU level after 2012.
    Farcas A; Balcescu T; Anghel L; Bucsa C; Mogoșan C
    Expert Opin Drug Saf; 2020 Jun; 19(6):755-762. PubMed ID: 32186202
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacovigilance in Europe: Place of the Pharmacovigilance Risk Assessment Committee (PRAC) in organisation and decisional processes.
    Laroche ML; Batz A; Géniaux H; Féchant C; Merle L; Maison P
    Therapie; 2016 Apr; 71(2):161-9. PubMed ID: 27080834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Investigating Overlap in Signals from EVDAS, FAERS, and VigiBase
    Vogel U; van Stekelenborg J; Dreyfus B; Garg A; Habib M; Hosain R; Wisniewski A
    Drug Saf; 2020 Apr; 43(4):351-362. PubMed ID: 32020559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An OMOP-CDM based pharmacovigilance data-processing pipeline (PDP) providing active surveillance for ADR signal detection from real-world data sources.
    Shin H; Lee S
    BMC Med Inform Decis Mak; 2021 May; 21(1):159. PubMed ID: 34001114
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A pharmacovigilance analysis of FDA adverse event reporting system events for romosozumab.
    Chen Z; Li M; Li S; Li Y; Wu J; Qiu K; Yu X; Huang L; Chen G
    Expert Opin Drug Saf; 2023 Apr; 22(4):339-342. PubMed ID: 36178002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems.
    Raschi E; Parisotto M; Forcesi E; La Placa M; Marchesini G; De Ponti F; Poluzzi E
    Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1098-1107. PubMed ID: 29174026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Analysis of Information on Drug Adverse Reactions Using U.S. Food and Drug Administration Adverse Event Reporting System (FAERS)].
    Nango D; Sekizuka T; Goto M; Echizen H
    Yakugaku Zasshi; 2022; 142(4):341-344. PubMed ID: 35370189
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Methods to Compare Adverse Events in Twitter to FAERS, Drug Information Databases, and Systematic Reviews: Proof of Concept with Adalimumab.
    Smith K; Golder S; Sarker A; Loke Y; O'Connor K; Gonzalez-Hernandez G
    Drug Saf; 2018 Dec; 41(12):1397-1410. PubMed ID: 30167992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanism-based Pharmacovigilance over the Life Sciences Linked Open Data Cloud.
    Kamdar MR; Musen MA
    AMIA Annu Symp Proc; 2017; 2017():1014-1023. PubMed ID: 29854169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of Hyponatraemia and Antidepressant Drugs: A Pharmacovigilance-Pharmacodynamic Assessment Through an Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Mazhar F; Pozzi M; Gentili M; Scatigna M; Clementi E; Radice S; Carnovale C
    CNS Drugs; 2019 Jun; 33(6):581-592. PubMed ID: 30977109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. How do patients contribute to signal detection? : A retrospective analysis of spontaneous reporting of adverse drug reactions in the UK's Yellow Card Scheme.
    Hazell L; Cornelius V; Hannaford P; Shakir S; Avery AJ;
    Drug Saf; 2013 Mar; 36(3):199-206. PubMed ID: 23444232
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combining Social Media and FDA Adverse Event Reporting System to Detect Adverse Drug Reactions.
    Li Y; Jimeno Yepes A; Xiao C
    Drug Saf; 2020 Sep; 43(9):893-903. PubMed ID: 32385840
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vaccine-based subgroup analysis in VigiBase: effect on sensitivity in paediatric signal detection.
    de Bie S; Verhamme KM; Straus SM; Stricker BH; Sturkenboom MC
    Drug Saf; 2012 Apr; 35(4):335-46. PubMed ID: 22435344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis.
    Gu T; Jiang A; Zhou C; Lin A; Cheng Q; Liu Z; Zhang J; Luo P
    Int J Cancer; 2023 Feb; 152(3):480-495. PubMed ID: 36274626
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New safety signals assessed by the Pharmacovigilance Risk Assessment Committee at EU level in 2014-2017.
    Farcaş A; Măhălean A; Bulik NB; Leucuta D; Mogoșan C
    Expert Rev Clin Pharmacol; 2018 Oct; 11(10):1045-1051. PubMed ID: 30269618
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced Paediatric Pharmacovigilance at the European Medicines Agency: A Novel Query Applied to Adverse Drug Reaction Reports.
    Blake KV; Saint-Raymond A; Zaccaria C; Domergue F; Pelle B; Slattery J
    Paediatr Drugs; 2016 Feb; 18(1):55-63. PubMed ID: 26597489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system.
    Shu Y; Ding Y; Dai B; Zhang Q
    Expert Opin Drug Saf; 2022 Apr; 21(4):563-572. PubMed ID: 34918584
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting Database.
    Caldito NG; Shirani A; Salter A; Stuve O
    Mult Scler; 2021 Jun; 27(7):1066-1076. PubMed ID: 32820687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.